CTOs on the Move


 
Enten is a Bethesda, MD-based company in the Business Services sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.enten.com
  • 8120 Woodmont Ave Ste 550
    Bethesda, MD USA 20814
  • Phone: 301.913.0010

Executives

Name Title Contact Details

Similar Companies

H-Cubed

H-Cubed is a Olmsted Falls, OH-based company in the Business Services sector.

Kitchen Angels

Kitchen Angels is a Santa Fe, NM-based company in the Business Services sector.

Advantage Custom Home Elctrncs

Advantage Custom Home Elctrncs is a Montrose, CO-based company in the Business Services sector.

Business Technology Partners

Founded in 1986, Business Technology Partners, LLP (BTP) is an integrated services firm, specializing in systems development and integration. We serve small and mid-size companies with a wide array of strategic solutions, as we work to help you identify

Denali Therapeutics

Denali Therapeutics is a clinical-stage biopharmaceutical company based in South San Francisco, California. The company focuses on developing therapies for neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, as well as lysosomal storage disorders like Hunter syndrome. Denali employs around 422 professionals and utilizes proprietary blood-brain barrier transport technologies to meet the medical needs of patients with brain-related disorders. Denalis innovative approach includes four engineered transport vehicle systems: Enzyme Transport Vehicle (ETV), Antibody Transport Vehicle (ATV), Protein Transport Vehicle (PTV), and Oligonucleotide Transport Vehicle (OTV). These technologies enable the delivery of various therapeutic agents to the brain. The company collaborates with major pharmaceutical partners, including Sanofi, AbbVie, and Takeda, to enhance the development of its pipeline products, which include DNL310 for Hunter syndrome and DNL151 for Parkinson’s disease. Denalis mission is to advance therapies that address the underlying causes of neurodegeneration, emphasizing a commitment to rigorous science and patient-focused innovation.